SanMelix Laboratories

SanMelix Laboratories

Early Stage

Helping You Heal with Honey

Helping You Heal with Honey


Raised to Date: Raised: $1,069,997

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common



SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Hollywood, Florida

Business Type


SanMelix Laboratories, with a pre-money valuation of $6.56 million, is raising funds on StartEngine. The company is creating a wound dressing formulation by combining the natural healing properties of buckwheat honey and some bioactive enhancements. The patents for these wound-care products are pending. SanMelix Laboratories was founded by Kenneth A. Sabacinski and Diana Sabacinski in 2017. The proceeds of the current crowdfunding round, with a minimum raise of $10,000 and a maximum raise of $107,000, will be used to complete the testing of the products and to prepare an inventory. The products of SanMelix are the first-ever honey-based formulations, and they are being tested currently by the US Air Force.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 06/19/2019
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
SanMelix Laboratories 01/10/2022 StartEngine $23,791,443 $136,960 Equity - Common Funded RegCF
SanMelix Laboratories 04/13/2021 StartEngine $6,561,600 $1,069,997 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article


The SanMelix Labs team has been selected as a “Top Deal” by KingsCrowd. This distinction is reserved for deals selected into the top 10% of our due diligence funnel. If you have questions regarding our deal diligence and selection methodology, please reach out to 

Next Section: Problem


In the US, chronic wounds affect around 6.5 million patients costing in excess of $25B to treat chronic open wounds. This is only increasing with the aging population, a sharp rise in diabetes (causes diabetic ulcerations), and the growing cost of healthcare. 

It is estimated that the advanced wound care market is to reach $14.89B by 2026 growing 4.5% from $10.34B in 2018. 

As mentioned above, this is driven by the continued rise of geriatric (65+) individual that will account for 42.5% of the total US population by 2030, and more than 100M US adults that are living with diabetes or prediabetes

Be it accidents caused by old age or ulcers caused by diabetes, wound care is a serious issue in these cohorts of patients that continue to grow at an uncomfortably elevated rate. 

In diabetics, ineffective wound care to get rid of these types of injuries are the leading cause of non-traumatic lower extremity amputations in the United States with about 14-24% requiring amputation. 

The only decent solution for patients today is Cefazolin, which is typically prescribed to patients with open wounds in an effort to prevent bacterial infection. However, numerous patient side effects, resistance to MRSA (a potentially deadly infection), and negative ecological effects on natural ecosystems are all issues that would lead one to surmise that a more natural solution for wound care is needed.  

A natural remedy for open wound care is needed if the healthcare community wants to decrease the number of non-traumatic amputations and lessen the impact on the environment. SanMelix Laboratories has a solution to offer. 

Next Section: Solution


SanMelix is offering a product that brings a solution to the healing of chronic wounds that has actually been around for thousands of years. In 3000 BC, Egyptians used honey as a wound treatment. 

Researchers found that the ancient Egyptians “wound salve” revealed that it is strongly bacteriocidal to Staphylococcus aureus, Escherichia coli, and coliform bacteria. Honey contains antibacterial agents that are active against nearly all bacteria, including common resistant strains found today. 

BEECure utilizes buckwheat honey compared to manuka honey because of its superior healing properties since buckwheat honey has higher anti-inflammatory and higher antioxidant activities. SanMelix’s advanced wound care products have been fortified with antimicrobials to ensure a higher standardization and broader spectrum antibacterial activity.

Buckwheat honey is higher in antioxidants and rich in vitamins which promotes healing in the body and supports immune function. Because honey draws moisture out of the wounds, it has the ability to eliminate bacteria. The high sugar content and low pH in the honey can also prevent bacteria and other microbes from growing in the wound. 

BEECure is made from buckwheat honey which is sustainably made and safe to the environment compared to synthetic and semi-synthetic drugs. Because of its bioactive enhancements, BEECure will improve skin and tissue regeneration and debriding action. This prevents the necessity for excess skin grafts or skin substitutes. 

SanMelix’s bioactive honey dressing with its patent pending is the first microbial barrier claim in the US. The dressing prevents biofilms from forming, control wound odor, reduces pain and treatment time while being more cost effective and more environmentally sound. Their honey treatment can also be used for acne treatment, diabetic foot cream, burn care ointment, radiodermatitis, eczema, eye drops, and diaper rash. 

Next Section: Other

Go To Market Plan & Challenges

SanMelix Laboratories is working with Trauma Insight for the testing phases of BEECure. Trauma Insight has formed a CRADA (cooperative research and development agreement between government agency and private company) with the United States Air Force. The Air Force is performing the 510(k) performance and microbial barrier testing. Currently, there’s an antibiotic-resistant infection affecting military personnel overseas. The BEECure dressings create a barrier between the insides of the body and the harsh environment that will keep the wound clean.

The advanced wound care MGO dressing is currently in the testing phase being carried out by the Air Force. The radiodermatitis cream is in the testing phase for product and packaging. While SanMelix has other ideas for where their formulated product can go, they are still just ideas that have not been created yet. 

A challenge associated with investing in a company that is still in the testing phase is simply time frame. However, the product seems sound and novel and the company is progressing nicely through test.

SanMelix is looking to continue testing the advanced wound care (AWC) products to obtain 510(k) pre-market clearance from the FDA while also continuing their pending patent formulation applications.

They are currently in negotiations with a European company to distribute its existing buckwheat honey CE mark products in order to secure a main and authentic raw buckwheat honey supplier. A concern associated with going with a European company and distributor is the increased regulations with bringing in products from overseas to the FDA to approve. An upside to having a distributor overseas is the opportunity to enter the global market more easily and seamlessly. 

SanMelix anticipates their customers will be the Veteran’s Affairs (VA) and Department of Defense (DoD), medical supply distributors, physician networks, hospitals, and indirect sales channel for over the counter opportunities. They plan to market directly to customers through digital marketing and social media. 


Next Section: Other

The Team

Dr. Kenneth A. Sabacinski is SanMelix Laboratories’ chief medical officer. Dr. Sabacinski is board certified and has over 30 years worth of clinical experience in foot and ankle medicine, surgery, and limb salvage. 

Dr. Sabacinski performed his internship, residency and fellowship training at the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. During his residency at the Beth Israel Deaconess Medical Center and the Joslin Diabetes Center, he was specifically trained in the treatment of acute and chronic diabetic foot ulcers. 

Diana Sabacinski is SanMelix Laboratories’ chief executive officer. Mrs. Sabacinski is a Certified Public Accountant (CPA) and Certified Fraud Examiner (CFE) with more than 25 years of public accounting and C-level management experience in the service, manufacturing, distribution, government contracting, and healthcare industries. She began her career at the international accounting firms of Deloitte, Haskins & Sells and Coopers & Lybrand. 

After obtaining her CPA license, she worked as a Vice President of Finance of a public manufacturing company. Subsequently from 1989 to 2001, she co-founded, co-owned, and operated a multi-location (7) computer training organization, ExecuTrain of Florida (ETF). 

Upon sale of the company, Mrs. Sabacinski started LKJ Associates, Inc., a consulting firm, to assist others in the development, planning, start-up, and operations of their companies and has provided advisory services at other firms as well. 

John Kaufman is SanMelix Laboratories’ director. Mr. Kaufman has 40 years of management experience working with and for the Government, business startups, and large-scale manufacturing, He is the founder or cofounder of three separate companies (InteSec Group Fla LLC, Be Power Tech Inc., International Battery). 

On the advisory board is Dr. Jason Green, a Board Certified Dermatologist, and founder of Green Dermatology & Cosmetic Center in Deerfield Beach, as well as 

Colonel George E. Peoples, a military career staff surgeon at a level I trauma center and multiple combat deployments. 

Additionally, Allison C. Komiyama, a former FDA reviewer who is an expert in regulatory submissions, quality systems, and biocompatibility evaluation is also working in an advisory role to the organization.

Next Section: Why We Like it

Why We Like it

  • Differentiated Solution: This product is a uniquely differentiated natural solution to solving wound care in the US, which is a fast growing market. With antibiotic concerning role in healthcare treatment, SanMelix has a product that can help curb and bypass resistance while improving overall care. SanMelix’s patent on the three products that are specific to buckwheat honey combined with antimicrobials increases the near to long term defensible moat of the business since replicating its formula is largely protected.
  • Government involvement: While government involvement can often mean slow moving and costly, in this case it actually can mean even more upside for the business. The reality is, the reason the government often gets involved in these types of projects is because of the recognition that there is a growing concern or issue facing the nation. In this case, growing resistance to synthetic drug solutions in the form of antibiotics is threatening our long term ability to treat patients. The Air Force’s role in testing this product for use in the field signals to big pharma and the general wound care market that new natural solutions are desired by the government to protect our long term interest as a country. SanMelix has a unique opportunity to win large contracts with the military for wound treatment while also putting on notice the general wound care market that a natural solution is a real viable alternative to current medical treatments.
  • Large Addressable Market: SanMelix is capitalizing on a $23.3B global wound healing market, a $3.6B global diabetic foot ulcer treatment market, and a $310.9M global radiodermatitis market. This is considering only the markets their current products would enter not the potential of other applications SanMelix Laboratories is considering. Big pharma, which will need to adapt to pressures for less utilization of antibiotics, could very likely look at this company as a prime acquisition target.

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
SanMelix Laboratories on StartEngine
Platform: StartEngine
Security Type: Equity - Common
Valuation: $6,561,600
Price per Share: $0.60

Follow company

Follow SanMelix Laboratories on StartEngine

Buy SanMelix Laboratories's Deal Report

Warning: according to the close date for this deal, SanMelix Laboratories may no longer be accepting investments.

SanMelix Laboratories Deal Report

Get KingsCrowd’s comprehensive report on SanMelix Laboratories including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether SanMelix Laboratories is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the SanMelix Laboratories deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge